Biocrine AB

17 patents currently held · Updated Nov 15, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Aug 2028

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

3 fees due Dec 23 to 30, 2026 · next Dec 23
2 fees due Jan 2 to 25, 2027 · next Jan 2
1 fee due Jun 3, 2027
The maintenance fee for Non-invasive in vivo imaging and methods for treating diabetes (US 10,493,108) comes due Jun 3, 2027. Unpaid by Dec 3, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 9,463,205	Non-invasive in vivo imaging and methods for treating type I diabetes In force Term ends Aug 27, 2028 · From the USPTO record	In force	Term ends Aug 27, 2028	From the USPTO record
US 10,207,012	Non-Invasive In Vivo Imaging and Methods for Treating Type I Diabetes In force Term ends Aug 27, 2028 · Medium confidence	In force	Term ends Aug 27, 2028	Medium confidence
US 10,493,108	Non-invasive in vivo imaging and methods for treating diabetes In force Ends no later than Aug 27, 2028 · From the USPTO record	In force	Ends no later than Aug 27, 2028	From the USPTO record
US 9,062,306	Methods for identifying compounds for treating type 1 diabetes In force Term ends Jan 9, 2029 · High confidence	In force	Term ends Jan 9, 2029	High confidence
US 9,068,973	Methods for treating and/or limiting development of diabetes In force Term ends Jun 25, 2032 · From the USPTO record	In force	Term ends Jun 25, 2032	From the USPTO record
US 9,353,183	Methods for treating and/or limiting development of diabetes In force Term ends Jun 25, 2032 · From the USPTO record	In force	Term ends Jun 25, 2032	From the USPTO record
US 9,744,232	Methods for treating and/or limiting development of diabetes In force Ends no later than Jun 25, 2032 · From the USPTO record	In force	Ends no later than Jun 25, 2032	From the USPTO record
US 10,226,530	Methods for treating and/or limiting development of diabetes In force Ends no later than Jun 25, 2032 · From the USPTO record	In force	Ends no later than Jun 25, 2032	From the USPTO record
US 9,702,867	Methods for monitoring physiological status of a body organ In force Ends no later than Jul 25, 2033 · From the USPTO record	In force	Ends no later than Jul 25, 2033	From the USPTO record
US 10,228,364	Methods for monitoring physiological status of a body organ In force Ends no later than Jul 25, 2033 · From the USPTO record	In force	Ends no later than Jul 25, 2033	From the USPTO record

10 of 17 patents shown.

Pro members see all 17.

Pro members: see all 17 patents

Also on record, not counted in the 17: 7 lapsed for an unpaid fee · 7 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 4 abandoned · 11 no status recorded

List them